Qingshan Yang1, Lisa S Chen, Sattva S Neelapu, Varsha Gandhi. 1. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX.
Abstract
BACKGROUND: SGI-1776 is a small-molecule Pim kinase inhibitor that primarily targets c-MYC-driven transcription and cap-dependent translation in mantle cell lymphoma (MCL) cells. Bendamustine is an alkylating chemotherapeutic agent approved for use in B-cell lymphoma that is known to induce DNA damage and initiate response to repair. MATERIALS AND METHODS: Our studies were conducted in MCL cell lines JeKo-1 and Mino, as well as primary B-cell lymphoma samples of MCL and splenic marginal zone lymphoma (SMZL), where we treated cells with SGI-1776 and bendamustine. We measured levels of cellular apoptosis, macromolecule synthesis inhibition, and DNA damage induced by drug treatments. RESULTS: Both SGI-1776 and bendamustine effectively induced apoptosis as single agents, and when used in combination, an additive effect in cell killing was observed in MCL cell lines JeKo-1 and Mino, as well as in MCL and SMZL primary cells. As expected, SGI-1776 was effective in inducing a decrease of global RNA and protein synthesis, and bendamustine significantly inhibited DNA synthesis and generated a DNA damage response. When used in combination, the effects were intensified in DNA, RNA, and protein synthesis inhibition compared with single-agent treatments. CONCLUSION: These data provide a foundation and suggest the feasibility of using Pim kinase inhibitors in combination with chemotherapeutic agents such as bendamustine in B-cell lymphoma.
BACKGROUND:SGI-1776 is a small-molecule Pim kinase inhibitor that primarily targets c-MYC-driven transcription and cap-dependent translation in mantle cell lymphoma (MCL) cells. Bendamustine is an alkylating chemotherapeutic agent approved for use in B-cell lymphoma that is known to induce DNA damage and initiate response to repair. MATERIALS AND METHODS: Our studies were conducted in MCL cell lines JeKo-1 and Mino, as well as primary B-cell lymphoma samples of MCL and splenic marginal zone lymphoma (SMZL), where we treated cells with SGI-1776 and bendamustine. We measured levels of cellular apoptosis, macromolecule synthesis inhibition, and DNA damage induced by drug treatments. RESULTS: Both SGI-1776 and bendamustine effectively induced apoptosis as single agents, and when used in combination, an additive effect in cell killing was observed in MCL cell lines JeKo-1 and Mino, as well as in MCL and SMZL primary cells. As expected, SGI-1776 was effective in inducing a decrease of global RNA and protein synthesis, and bendamustine significantly inhibited DNA synthesis and generated a DNA damage response. When used in combination, the effects were intensified in DNA, RNA, and protein synthesis inhibition compared with single-agent treatments. CONCLUSION: These data provide a foundation and suggest the feasibility of using Pim kinase inhibitors in combination with chemotherapeutic agents such as bendamustine in B-cell lymphoma.
Authors: Hesham M Amin; Timothy J McDonnell; L Jeffrey Medeiros; Georgios Z Rassidakis; Vasiliki Leventaki; Sean L O'Connor; Michael J Keating; Raymond Lai Journal: Arch Pathol Lab Med Date: 2003-04 Impact factor: 5.534
Authors: Tint Lwin; Lori A Hazlehurst; Sophie Dessureault; Raymond Lai; Wenlong Bai; Eduardo Sotomayor; Lynn C Moscinski; William S Dalton; Jianguo Tao Journal: Blood Date: 2007-05-14 Impact factor: 22.113
Authors: Eric D Hsi; Sin-Ho Jung; Raymond Lai; Jeffrey L Johnson; James R Cook; Dan Jones; Sven Devos; Bruce D Cheson; Lloyd E Damon; Jonathan Said Journal: Leuk Lymphoma Date: 2008-11
Authors: Esperanza Martín-Sánchez; Lina Odqvist; Socorro M Rodríguez-Pinilla; Margarita Sánchez-Beato; Giovanna Roncador; Beatriz Domínguez-González; Carmen Blanco-Aparicio; Ana M García Collazo; Esther González Cantalapiedra; Joaquín Pastor Fernández; Soraya Curiel del Olmo; Helena Pisonero; Rebeca Madureira; Carmen Almaraz; Manuela Mollejo; F Javier Alves; Javier Menárguez; Fernando González-Palacios; José Luis Rodríguez-Peralto; Pablo L Ortiz-Romero; Francisco X Real; Juan F García; James R Bischoff; Miguel A Piris Journal: PLoS One Date: 2014-11-11 Impact factor: 3.240
Authors: Neha S Bhise; Lata Chauhan; Miyoung Shin; Xueyuan Cao; Stanley Pounds; Vishal Lamba; Jatinder K Lamba Journal: Front Pharmacol Date: 2016-01-28 Impact factor: 5.810
Authors: Fabiola Cervantes-Gomez; Christine M Stellrecht; Mary L Ayres; Michael J Keating; William G Wierda; Varsha Gandhi Journal: Oncotarget Date: 2019-04-19
Authors: Eriko Katsuta; Malgorzata Gil-Moore; Justine Moore; Mohamed Yousif; Alex A Adjei; Yi Ding; Justin Caserta; Carmen M Baldino; Kelvin P Lee; Irwin H Gelman; Kazuaki Takabe; Mateusz Opyrchal Journal: Int J Oncol Date: 2022-08-03 Impact factor: 5.884
Authors: Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-07-26